Karyotype evolution in a patient with down syndrome and acute leukemia following a congenital leukemoid reaction

Jeffrey R. Sawyer(Arkansas Children's Hospital), David Becton(University of Arkansas for Medical Sciences), David R. Head(University of Southern California), Gary J. Roloson(University of Arkansas for Medical Sciences)
Medical and Pediatric Oncology
January 1, 1994
10.1002/mpo.2950220610
Cited by 10

Related Papers

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study
|Blood|2000|1.6k
Age and acute myeloid leukemia
|Blood|2006|1.4k
Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study
|Blood|1997|869
Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.
|Journal of Clinical Oncology|1990|786
Acute Myeloid Leukemia in Children Treated with Epipodophyllotoxins for Acute Lymphoblastic Leukemia
|New England Journal of Medicine|1991|722